28.3% in phase 3. Three receptors. Zero approvals. Everything the trials actually showed, without the hype.
Retatrutide is the first triple agonist: GIP + GLP-1 + glucagon. The glucagon piece is the new idea, recruiting calorie burn on top of appetite suppression. TRIUMPH-1 (2,339 adults, 80 weeks) put the 12 mg dose at 28.3% mean weight loss, with 45.3% of participants losing 30% or more. A two-year extension averaged 30.3%. It is still investigational. An FDA filing is expected in Q1 2027.
| Trial | Population | Dose | Result |
|---|---|---|---|
| TRIUMPH-1 (phase 3) | 2,339 adults, obesity, no diabetes | 12 mg weekly | 28.3% at 80 weeks |
| 2-year extension | TRIUMPH-1 continuers | 12 mg weekly | 30.3% average |
| 30%+ responders | TRIUMPH-1, 12 mg | 45.3% of participants |
GLP-1 and GIP suppress appetite. Glucagon raises energy expenditure. Nobody had combined all three in one molecule before, because glucagon also raises blood sugar, which is exactly what you do not want in a metabolic drug. The bet behind retatrutide is that the GIP/GLP-1 components offset the glucose risk while the glucagon component adds burn. TRIUMPH-1 suggests the bet is paying off. The long-term safety database is still young, and that is the honest caveat on every triple-agonist claim you will read.
Against tirzepatide's 20.9% (SURMOUNT-1) and semaglutide's 14.9% (STEP-1), retatrutide's 28.3% is the biggest headline number in the class. Cross-trial comparisons come with the usual warnings: different populations, durations, and dropout handling. The full breakdown is in our tirzepatide vs retatrutide comparison.
No. Retatrutide is investigational and not approved anywhere in the world. An FDA filing is expected in Q1 2027. Anything sold today is sold as a research chemical, not a medicine.
Tirzepatide hits two receptors (GIP + GLP-1). Retatrutide adds a third: the glucagon receptor, which is thought to increase energy expenditure on top of appetite suppression. In separate trials, retatrutide's 28.3% (TRIUMPH-1) topped tirzepatide's 20.9% (SURMOUNT-1), but there has never been a head-to-head trial.
The usual incretin GI effects: nausea, vomiting, diarrhea, dose-dependent and worst during dose escalation. The glucagon component is the main tolerability question researchers are watching.
TRIUMPH-1 tested weekly doses up to 12 mg over 80 weeks. The 12 mg dose produced the headline 28.3% result, with 45.3% of participants losing at least 30% of body weight.
We sell strictly as a laboratory research chemical, the same as every compound on this site. Unapproved status is exactly why batch documentation matters more, not less.
All compounds are sold strictly as laboratory research chemicals, not for human consumption. Trial figures are mean changes in the cited trial populations.
